Human antibodies for novel targets and underserved diseases
argenx develops novel human antibody medicines to unlock novel & complex targets addressing diseases that are underserved by current therapies. We combine our unique antibody discovery platform, SIMPLE Antibody™ with Fc engineering technologies to create highly differentiated antibodies with distinctive therapeutic qualities.
argenx creates antibodies with first- and best-in-class therapeutic potential. We have a diversified pipeline with two potential oncology drugs in the clinic, two autoimmune assets in the clinic and several product leads in preclinical development.